1. Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation
- Author
-
Universidad de Sevilla. Departamento de Medicina, Instituto de Salud Carlos III, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Rey, E., Ampuero Herrojo, Javier, Molina-Jiménez, F., García-García, Y., Muñoz Hernández, Rocío, Romero Gómez, Manuel, García-Monzón, C., Majano, P., González-Rodríguez, A., Universidad de Sevilla. Departamento de Medicina, Instituto de Salud Carlos III, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Rey, E., Ampuero Herrojo, Javier, Molina-Jiménez, F., García-García, Y., Muñoz Hernández, Rocío, Romero Gómez, Manuel, García-Monzón, C., Majano, P., and González-Rodríguez, A.
- Abstract
In the present study, we have demonstrated that sofos buvir (SOF) treatment improves systemic insulin resis tance in hepatitis C virus (HCV)-patients, and, for the first time, revealed which molecular mechanisms are involved in SOF effects on the impaired insulin response induced by HCV in hepatocytes.
- Published
- 2021